As a superficial tumor, the causes of death in patients with breast cancer are reported to be due to cancer metastasis and/or relapse, which are significantly associated with the favorable tumor microenvironment [4]
Production of these reactive oxygen species is known to occur as a result of a few different mechanisms: 1) mitochondrial origin in which free radicals either escape scavenging enzymes or develop due to an error in oxidative processes, 2) inside the capillary endothelium where a hypoxic and reoxygenation process is created during intense exercise as well as during various types of cardiovascular disease, and 3) an oxidative burst from inflammatory cells which are commonly mobilized as a result of the muscle or tissue damage which is well-documented with extended or eccentric-based exercise[1]
The GSTM1 polymorphism is associated with a decline in the expression of the protein, which is a risk factor
This review summarizes how mitochondrial dysfunction exacerbates inflammation and impedes the healing process in DW through mechanisms such as excessive reactive oxygen species (ROS) production, mitochondrial DNA (mtDNA) leakage, and aberrant inflammasome activation
Novel material-based approaches are also being investigated to advance pulmonary drug delivery, such as thin-film freezing, supercritical fluid technology, nano-in-micro particle systems, crystal-engineered microstructures, and porous drug carriers, all of which aim to improve drug stability, bioavailability, and pulmonary retention [209, 210]
/assets/images/provider/photos/2775905.jpeg)
